Wall Street analyst estimates for Coya Therapeutics, Inc. (COYA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 0.00 |
| EV / EBITDA | 1951.45 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $6.0M | $3.6M | $7.9M |
| Cost of Revenue | 0 | 0 | $4.4M | $5.5M | $11.9M | $27361 |
| Gross Profit | 0 | 0 | -$4.4M | $500679 | -$8.3M | $7.9M |
| Research & Development | $373454 | $2.5M | $4.9M | $6.0M | $11.9M | $16.7M |
| Selling, General & Admin | $668700 | $2.3M | $4.8M | $7.8M | $8.9M | $11.4M |
| Operating Expenses | $1.0M | $4.9M | $5.4M | $8.4M | $8.9M | $28.2M |
| Operating Income | -$1.0M | -$4.9M | -$9.8M | -$7.9M | -$17.2M | -$20.3M |
| EBITDA | 0 | -$4.9M | -$9.3M | -$7.3M | -$17.2M | -$21.2M |
| Interest Expense | $38976 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$1.1M | -$4.9M | -$12.2M | -$7.3M | -$15.6M | -$21.2M |
| Income Tax | 0 | 0 | 0 | $723852 | -$720287 | $3089 |
| Net Income | -$1.1M | -$4.9M | -$12.2M | -$8.0M | -$14.9M | -$21.2M |
| EPS | $-0.42 | $-0.74 | $-1.23 | $-0.79 | $-0.98 | $-1.27 |
| EPS (Diluted) | $-0.42 | $-0.74 | $-1.23 | $-0.79 | $-0.98 | $-1.27 |
| Shares Outstanding (Diluted) | $2.6M | $6.6M | $9.9M | $10.2M | $15.2M | $16.7M |
Price
| Price | $4.46 |
| Market Cap | $105M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLNN · CNTX · IMMX · MGNX · ORMP · OVID · PLRX
Explore sector: Healthcare · Biotechnology
More sections of COYA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks